Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 416 of 6351
-
New psoriasis drug could be cheaper alternative to tremfya
Disease control Recruiting nowIt is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included an…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New magnetic device aims to boost stroke recovery
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate whether low-frequency, low-intensity transcranial magnetic stimulation (ELF-MF), delivered by the I-NIC medical device, is effective and safe in treating patients with acute ischemic stroke. The study aims to answer the following qu…
Sponsor: IGEA • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for Hard-to-Treat lung cancer: drug combo may make surgery possible
Disease control Not yet recruitingThis is a multicenter, phase 2 non-randomized study to investigate the clinical feasibility and therapeutic efficacy of employing a MDT-based strategy in unresectable stage III ALK positive NSCLC following neoadjuvant alectinib in combination with platinum-based chemotherapy. Par…
Phase 2 • Sponsor: Wen-zhao ZHONG • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a common diabetes drug be the key to better stroke recovery?
Disease control Not yet recruitingIntracerebral hemorrhage (ICH) is a devastating form of acute stroke with poor clinical outcomes. Although ICH accounted only for 28.8% of incident strokes, it was responsible for nearly half of the long-term burden of stroke measured in disability-adjusted life years . In contra…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy-Chemo cocktail shows promise for shrinking cervical tumors before surgery
Disease control Not yet recruitingThis is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of QL1706 combined with cisplatin and paclitaxel as neoadjuvant therapy in patients with FIGO 2018 stage IB1-IB3 cervical cancer undergoing conservative surgery. The primary e…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New light treatment could replace surgery for cervical precancer
Disease control Not yet recruitingThis is a prospective, multicenter real-world study evaluating the effectiveness and safety of hexaminolevulinate photodynamic therapy (HAL-PDT) in patients with cervical intraepithelial neoplasia grade 2 (CIN2). Treatment is guided by colposcopic response: patients receive 2, 3,…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis is a Phase I/II study. The Phase I part will evaluate the safety and tolerability of sonrotoclax in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), using a standard 3+3 dose-escalation design, to determine the …
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
HIV drug shows promise to reboot immune system in Non-Responders
Disease control Recruiting nowThis study focuses on people with HIV who experience incomplete immune reconstitution despite suppressive antiretroviral therapy (ART), characterized by persistently low CD4⁺ T cell counts and residual inflammation. The underlying cause is largely attributed to the persistent HIV…
Phase 2 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a shot replace daily HIV pills? new trial tests Two-Injection combo
Disease control Recruiting nowThe study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in virological…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo may boost surgery success in returning liver cancer
Disease control Not yet recruitingThis is a single-arm, phase II clinical study designed to evaluate the efficacy and safety of a recombinant PD-1/IL-2 bispecific antibody, as neoadjuvant therapy in hepatocellular carcinoma (HCC) patients who experienced early recurrence after curative hepatectomy and were suitab…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New radiation approach aims to cut treatment time for early breast cancer
Disease control Not yet recruitingThis prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
40,000 people test app to outsmart diabetes
Prevention Recruiting nowThe overall aim of the study is to investigate the incidence of type 2 diabetes in individuals who have access to a digital intervention tool as compared with randomized controls during three years. The tool is based on self-affirmation theory and has large emphasis on self-refle…
Sponsor: Region Skane • Aim: Prevention
Last updated Jun 27, 2026 14:03 UTC
-
Pig liver scaffold may speed healing of stubborn diabetic wounds
Disease control Recruiting nowThis study is designed to evaluate whether the Miro3D Wound Matrix, when used in addition to standard of care, improves healing outcomes in patients with chronic diabetic foot ulcers. Diabetic foot ulcers are a common and serious complication of diabetes and may be difficult to …
Sponsor: Reprise Biomedical, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to wake up immune system against Hard-to-Treat leukemia
Disease control Recruiting nowThe purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control By invitation onlyA New Treatment Opportunity for Patients with Advanced Colorectal Cancer Refractory to Standard Chemotherapy: Clinical Trial of Capecitabine plus Lenvatinib Combination Therapy
Phase 1/2 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
App-Based therapy aims to curb Self-Harm in teens
Disease control Not yet recruitingThe goal of this randomized, parallel-controlled clinical trial is to investigate multi-dimensional biomarkers (blood, brain imaging, clinical information, and symptom assessment) in adolescents with Non-Suicidal Self-Injury (NSSI) and to evaluate the therapeutic and prognostic e…
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental injection aims to combat Life-Threatening liver failure
Disease control Recruiting now\*\*Document Name: This Trial is a Phase II Clinical Study.docx\*\* \*\*Document Content:\*\* * This trial is a Phase II clinical study, conducted in two stages: * \*\*Phase IIa:\*\* A sentinel, single-arm design will be employed. A total of 12 early ACLF subjects are expected t…
Phase 2 • Sponsor: Shenzhen Third People's Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a faster, Higher-Power heart ablation beat the standard for AFib?
Disease control Recruiting nowAtrial fibrillation (AF) is the most common cardiac arrhythmia and represents one of the leading causes of cardiovascular morbidity and mortality. According to current data, AF is associated with approximately 20% of all ischemic strokes, while the risk of stroke in patients with…
Sponsor: Bakulev Scientific Center of Cardiovascular Surgery • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Mapping the Body's ICU journey: a new monitor could spot danger signs early
Knowledge-focused OngoingCritically ill patients can deteriorate rapidly across multiple organ systems. Most intensive care unit (ICU) risk tools rely on measurements collected at a single time point and may not fully capture how physiology evolves or how quickly a patient recovers from disturbance. This…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can a common diabetes drug combo help those with cancer history?
Disease control OngoingUse Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
Phase 2/3 • Sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC